|
|
||||||||
Original Research |
Rajesh Nayak, PhD, National Center for Toxicological Research, United States Food and Drug Administration, Jefferson, Arkansas
Veronica Call, BS, Office of Regulatory Affairs/Arkansas Regional Laboratory, United States Food and Drug Administration, Jefferson, Arkansas
Pravin Kaldhone, MS, National Farm Medicine Center, Marshfield Clinic Research Foundation, Marshfield, Wisconsin and Department of Biology, University of Central Arkansas Conway, Arkansas
Cynthia Tyler, MS, National Farm Medicine Center Marshfield Clinic Research Foundation, Marshfield, Wisconsin and Department of Biology, University of Central Arkansas Conway, Arkansas
Gwendolyn Anderson, BS, Office of Regulatory Affairs/Arkansas Regional Laboratory, United States Food and Drug Administration, Jefferson, Arkansas
Sarah Phillips, PhD, Office of Regulatory Affairs/Arkansas Regional Laboratory, United States Food and Drug Administration, Jefferson, Arkansas
Khalil Kerdahi, BS, Office of Regulatory Affairs/Arkansas Regional Laboratory, United States Food and Drug Administration, Jefferson, Arkansas
Steven L. Foley, PhD, Office of Regulatory Affairs/Arkansas Regional Laboratory, United States Food and Drug Administration, Jefferson, Arkansas and National Farm Medicine Center, Marshfield Clinic Research Foundation, Marshfield, Wisconsin and Department of Biology, University of Central Arkansas Conway, Arkansas
Reprint Requests: Steven L. Foley, PhD, Marshfield Clinic Research Foundation 1000 North Oak Avenue Marshfield, WI 54449 Tel: 715-389-4012 Fax: 715-389-3808 E-mail: foley.steven{at}mcrf.mfldclin.edu
Received: October 2, 2006.
Revised: December 28, 2006.
Accepted: February 21, 2007.
| Abstract |
|---|
|
|
|---|
Design: S. enterica serovar Heidelberg (n=105) strains were tested using 4 different AST methods: agar disk diffusion, broth microdilution using Sensititre with the NARMS (CMV1AGNF) panel, manual broth microdilution and Vitek with GNS-207 cards.
Methods: AST was performed using standardized methods and Clinical and Laboratory Standards Institute recommended quality control organisms. Eight drugs were common to all testing methods including amikacin, amoxicillin/clavulanic acid, ampicillin, chloramphenicol, ciprofloxacin, gentamicin, tetracycline and trimethoprim/sulfamethoxazole.
Results: No resistance to amikacin and ciprofloxacin was detected. Overall, the agreement of the AST results among all four methods for the drugs tested was: amikacin (100%), amoxicillin/clavulanic acid (96.1%), ampicillin (97.1%), chloramphenicol (96.2%), ciprofloxacin (100%), gentamicin (80.0%), tetracycline (80.0%) and trimethoprim/sulfamethoxazole (94.3%). There was 97.1%, 95.5% and 98.0% overall agreement between the reference diffusion method and the manual broth microdilution, Sensititre microdilution and Vitek methods, respectively.
Conclusion: The study indicated that AST methods correlated with one another when testing S. enterica serovar Heidelberg isolates, with a few exceptions. In general, discrepancies among the methods were due to isolates being interpreted as intermediately susceptible or due to an increased number of resistances detected with Sensititre and a lower number with Vitek.
Key Words: Antimicrobial susceptibility testing Broth microdilution Disk diffusion Salmonella enterica serotype Heidelberg
S almonella enterica serovar Heidelberg strains are important animal pathogens which are increasingly becoming human pathogens and a considerable public health concern. Each year there are an estimated 1.4 million cases of Salmonella infections in the United States that result in 17,000 hospitalizations and 585 deaths.1 Among the Salmonella species responsible for causing human disease, Heidelberg is the fourth most commonly implicated serotype.2 Over the past 10 years, the incidence of S. enterica serovar Heidelberg infections in humans has increased by 25%.3 Among the food animals, S. enterica serovar Heidelberg is the most commonly identified serotype among isolates originating from turkeys and chickens analyzed by the National Veterinary Services Laboratory.4 In addition, S. enterica serovar Heidelberg strains are found throughout the turkey production and processing environments, and in retail turkey products.57 Because there has been a significant increase in per capita consumption of poultry products over the past 50 years, and because the majority of salmonellosis cases are associated with consumption of contaminated foods,1,8 the contamination of poultry products with S. enterica serovar Heidelberg has become a major health concern.9 Adding to this concern is the emergence and spread of antimicrobial resistant strains of S. enterica serovar Heidelberg9,10 potentially caused by the use of antimicrobial agents in the animal production environment and is threatening the management of salmonellosis in both veterinary and human clinical practice. It is important, therefore, to compare the results of common susceptibility testing methods to facilitate the sharing of susceptibility data from this potentially emerging pathogen.
Antimicrobial susceptibility testing (AST) is critical to clinical and diagnostic microbiology as it can provide insights into treatment options to combat potentially antimicrobial-resistant infectious diseases. The problems of antimicrobial resistance in foodborne pathogens led the US federal government to develop the National Antimicrobial Resistance Monitoring System (NARMS), a multi-agency collaboration between the Food and Drug Administration (FDA), Centers for Disease Control and Prevention (CDC), and Department of Agriculture (USDA).11 Through NARMS, antimicrobial resistance is monitored in enteric bacteria isolated from human infections, food animal slaughter and diagnostic samples, and retail foods.5,9 The AST method utilized by the NARMS program is a broth microdilution method, which provides a quantitative measure of susceptibility.5 Interpretation of the results of broth microdilution and other AST methods is often guided by criteria set by the Clinical Laboratory Standards Institute (CLSI).12
Due to their wide application in clinical diagnostics and public health, a number of methods and instrumentation have been developed to carry out AST.1315 With the diversity of testing methods available, most laboratories lack all the different resources (automated and semi-automated systems) to carry out AST. Hence, it is important to determine whether the interpreted results obtained by the different methods correlate with one another to ensure that the results obtained in multiple laboratories could be compared without the time delay and added expense of sending the isolates to a reference laboratory. Time is of the essence in cases of widespread disease outbreaks or potential bioterrorism events, where large numbers of isolates would be screened to determine if they are resistant to the first-line drug therapy.1620 In the current study, we compared the results of four different AST methods (agar disk diffusion method, manual broth microdilution, semi-automated broth microdilution, and Vitek) in S. enterica serovar Heidelberg isolates.
| Material and Methods |
|---|
|
|
|---|
Susceptibility Testing Methods
Four different typing methods were used in this study to evaluate the accuracy of the method to correctly determine the antibiotic susceptibility of S. enterica serovar Heidelberg isolates. Each of the methods screened a panel of antimicrobial agents (approximately 15). Among the agents tested, eight drugs were common in all four methods and were used for the evaluating the accuracy of the different AST methods. Furthermore, as each method has different measurement endpoints, we collectively interpreted the results based on whether a bacterial strain was susceptible, intermediate-susceptible or resistant to the antimicrobial agent. The eight common drugs evaluated were amikacin, amoxicillin/clavulanic acid, ampicillin, chloramphenicol, ciprofloxacin, gentamicin, tetracycline and trimethoprim/sulfamethoxazole.
Agar disk diffusion testing was carried out on the isolates following standard protocols and the interpretive guidelines from CLSI to determine the susceptibility profiles of the isolates.19 The following antimicrobial agents were tested: amoxicillin/clavulanic acid (20/10 µg/disk), ampicillin (10 µg/disk), amikacin (30 µg/disk), ceftiofur (30 µg/disk), ceftriaxone (30 µg/disk), cefoxitin (30 µg/disk), ciprofloxacin (5 µg/disk), chloramphenicol (30 µg/disk), gentamicin (10 µg/disk), kanamycin (30 µg/disk), nalidixic acid (30 µg/disk), streptomycin (10 µg/disk), sulfamethoxazole (300 µg/disk), tetracycline (30 µg/disk), and trimethoprim/sulfamethoxazole (1.25/23.75 µg/disk). Following 18 to 20 hours of incubation at 35°C, the plates were examined and the zone of inhibition measured for each antibiotic.
The manual broth microdilution susceptibility testing was performed using susceptibility plates prepared in the test laboratory. Two-fold serial dilutions of the antimicrobial agents were added to the wells of a 96-well microtiter plate. The following agents were tested (dilution ranges): amoxicillin/clavulanic acid (2/1 µg/ml to 64/32 µg/ml), ampicillin (0.51024 µg/ml), amikacin (4128 µg/ml), apramycin (0.51024 µg/ml), ceftriaxone (264 µg/ml), cefoxitin (264 µg/ml), cephalothin (264 µg/ml), ciprofloxacin (0.51024 µg/ml), chloramphenicol (0.51024 µg/ml), gentamicin (0.51024 µg/ml), kanamycin, (0.51024 µg/ml) nalidixic acid (4128 µg/ml), streptomycin (0.51024 µg/ml), sulfamethoxazole (4128 µg/ml), tetracycline (0.51024 µg/ml) and trimethoprim/sulfamethoxazole (0.24/4.8 µg/ml to 7.68/153.6 µg/ml). Bacterial suspensions were prepared by diluting cells in sterile Mueller-Hinton broth and the cell density was adjusted to 5 x 105 CFU/ml. The cell suspensions were added to the plates (total volume/well=50 µl). The plates were incubated for 18 to 20 hours at 35°C and the growth (turbidity) was measured at 600 nm.
The Sensititre automated antimicrobial susceptibility system (Trek Diagnostic Systems, Westlake, OH) was also used for broth microdilution testing and interpreted according to CLSI guidelines for broth microdilution methods.21 Sensititre susceptibility testing was performed according to the manufacturers instructions with the CMV1AGNF plates (Trek Diagnostics) utilized by NARMS. Each plate contained the following drugs: amoxicillin/clavulanic acid, ampicillin, amikacin, ceftiofur, ceftriaxone, cefoxitin, ciprofloxacin, chloramphenicol, gentamicin, kanamycin, nalidixic acid, streptomycin, sulfamethoxazole, tetracycline and trimethoprim/sulfamethoxazole.
Vitek testing was carried out using commercially available veterinary drug cards (GNS-207) according to the manufacturers instructions (BioMérieux, Inc., Durham, NC). The drugs included in the panel were amoxicillin/clavulanic acid, ampicillin, amikacin, carbenicillin, ceftiofur, cephalothin, ciprofloxacin, chloramphenicol, enrofloxacin, gentamicin, nitrofurantoin, piperacillin, tetracycline, ticarcillin, tobramycin and trimethoprim/sulfamethoxazole. Interpretive criteria (extrapolated from CLSI guidelines) provided by the manufacturer were used to interpret the results.
Quality Control Testing
For the agar disk diffusion testing, Escherichia coli (ATCC 25922) was used as the quality control strain for testing. For the broth microdilution and Vitek methods, E. coli (ATCC 25922), Staphylococcus aureus (ATCC 29213), Enterococcus faecalis (ATCC 29212) and Pseudomonas aeruginosa (ATCC 27853) were used as quality control strains. Quality control testing was performed for each method on the day AST testing was performed and the results were interpreted as described by CLSI. If the test results for the quality control strains were outside the prescribed control ranges, all susceptibility testing performed on that day was repeated. The AST methods and the agar disk diffusion testing were performed in laboratories affiliated with the studys principal investigators (Nayak and Foley) and the results compared to ensure agreement of test methodology for the drugs being studied.
Data Analysis
Data analysis for the experiments was carried out as described by Guthrie et al,13 with some modifications. The AST results for the isolates studied were interpreted according to the guidelines set by CLSI for agar disk diffusion, manual broth microdilution, and Sensititre microdilution. The Vitek results used were those reported by the Vitek system as susceptible, ntermediate-susceptible, or resistant. The agar disk diffusion method was utilized as a reference method in this study. The interpreted results were compared to determine the percent agreement among the test method and the reference, and to determine any discrepancies among the results. The discrepancies were classified as being very major errors if the isolate was interpreted as susceptible by the method being evaluated and resistant by the reference method. A major error was detected if the isolate was interpreted as resistant by the method being evaluated and susceptible by the reference method, and the discrepancy was considered a minor error if an isolate was classified as intermediate-susceptible by either the test or reference method and the other test classified the isolate as either resistant or susceptible.13
| Results |
|---|
|
|
|---|
|
| Discussion |
|---|
|
|
|---|
When the results of this study were compared to other AST comparison studies, the results were relatively similar. The error rates reported by Guthrie et al13 had a similar pattern to the present study. In the majority of drugs tested with Streptococcus pneumoniae, there were few errors. However, there was an elevation in the number of very major and major errors for trimethoprim/sulfamethoxazole.13 The pattern of these findings were similar to what was seen for gentamicin and tetracycline in the present study, which had higher error rates compared to the rest of the drugs tested. Studies that examined susceptibility testing in gram negative organisms also had similar results to the current study, with overall categorical error rates of around 2% for Vitek and broth microdilution testing, which was similar to the 2.1% to 3.3% range in our study.22,23 When a consortium in Europe compared disk diffusion, broth microdilution and agar breakpoint testing with Salmonella isolates, they found a high level of agreement among the results of each method to detect resistant organisms.24 These findings were similar to our results for the most part, with the exception of gentamicin and tetracycline, which had higher error rates in our study. The finding that gentamicin and tetracycline had the highest error rates in our study was not unique. Other multi-method AST study findings for gram negative organisms have found similar findings for gentamicin and tetracycline compared to the other drugs tested.25,26
The finding of only a single very major and a single major error for trimethoprim/sulfamethoxazole was notable because trimethoprim/sulfamethoxazole is one of the agents of choice for the treatment of invasive salmonellosis.27 Results indicating that gentamicin and tetracycline had the highest error rates were also interesting because these drugs are not typically used for the treatment of salmonellosis, thus the elevated error levels in the testing of these agents will likely have limited impact on clinical outcomes. Taken together, if the findings of ideal drugs have the lowest and highest error rates for Salmonella, they would likely be similar to the results of our study, with the more clinically important drugs (such as trimethoprim/sulfamethoxazole and ciprofloxacin) having low error rates and those used less frequently, if at all (gentamicin and tetracycline), having the higher error rates. The results of this study demonstrated that even though the methods have been thoroughly validated by CLSI and method developers, there could be some variability among laboratory personnel. Overall, the study confirmed that the interpreted results of the methods were similar for susceptibility testing of S. enterica serovar Heidelberg isolates with some noted exceptions. Therefore, under most circumstances, the interpreted results of the susceptibility testing methods evaluated in this study can be compared to results of other testing methods, potentially permitting greater sharing of susceptibility testing results among scientists and diagnosticians.
|
|
|---|
Disclaimer: The use of trade names is for identification purposes only and does not imply endorsement by the US Food and Drug Administration or the US Department of Health and Human Services. Views presented in this manuscript do not necessarily reflect those of the FDA.
| References |
|---|
|
|
|---|
| ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |